Emerging,O
Microbes,O
&,O
Infections,CAUSE_OF_DEATH
Risk,O
factors,O
associated,O
with,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
:,O
a,O
retrospective,O
cohort,O
study,O
based,O
on,O
con,O
‐,O
tacts,O
Tao,PERSON
Liu,PERSON
.,O
Wenjia,PERSON
Liang,PERSON
.,O
Haojie,PERSON
Zhong,PERSON
.,O
Jianfeng,PERSON
He,O
.,O
Zihui,PERSON
Chen,PERSON
.,O
Guanhao,O
He,O
.,O
Tie,O
Song,O
.,O
Shaowei,PERSON
Chen,PERSON
.,O
Ping,PERSON
Wang,PERSON
.,O
Jialing,PERSON
Li,PERSON
.,O
Yunhua,PERSON
Lan,PERSON
.,O
Mingji,PERSON
Cheng,PERSON
.,O
Jinxu,PERSON
Huang,PERSON
.,O
Jiwei,PERSON
Niu,PERSON
.,O
Liang,PERSON
Xia,PERSON
.,O
Jianpeng,PERSON
Xiao,PERSON
.,O
Jianxiong,PERSON
Hu,PERSON
.,O
Lifeng,PERSON
Lin,PERSON
.,O
Qiong,PERSON
Huang,PERSON
.,O
Zuhua,PERSON
Rong,PERSON
.,O
Aiping,PERSON
Deng,PERSON
.,O
Weilin,PERSON
Zeng,PERSON
.,O
Jiansen,PERSON
Li,PERSON
.,O
Xing,PERSON
Li,PERSON
.,O
Xiaohua,PERSON
Tan,PERSON
.,O
Min,PERSON
Kang,PERSON
.,O
Lingchuan,PERSON
Guo,PERSON
.,O
Zhihua,PERSON
Zhu,PERSON
.,O
Dexin,PERSON
Gong,PERSON
.,O
Guimin,PERSON
Chen,PERSON
.,O
Moran,PERSON
Dong,PERSON
&,O
Wenjun,O
Ma,O
He,O
.,O
Tie,O
Song,O
.,O
Shaowei,PERSON
Chen,PERSON
.,O
Ping,PERSON
Wang,PERSON
.,O
Jialing,PERSON
Li,PERSON
.,O
Yunhua,PERSON
Lan,PERSON
.,O
Mingji,PERSON
Cheng,PERSON
.,O
Jinxu,PERSON
Huang,PERSON
.,O
Jiwei,PERSON
Niu,PERSON
.,O
Liang,PERSON
Xia,PERSON
.,O
Jianpeng,PERSON
Xiao,PERSON
.,O
Jianxiong,PERSON
Hu,PERSON
.,O
Lifeng,PERSON
Lin,PERSON
.,O
Qiong,PERSON
Huang,PERSON
.,O
Zuhua,PERSON
Rong,PERSON
.,O
Aiping,PERSON
Deng,PERSON
.,O
Weilin,PERSON
Zeng,PERSON
.,O
Jiansen,PERSON
Li,PERSON
.,O
Xing,PERSON
Li,PERSON
.,O
Xiaohua,PERSON
Tan,PERSON
.,O
Min,PERSON
Kang,PERSON
.,O
Lingchuan,PERSON
Guo,PERSON
.,O
Zhihua,PERSON
Zhu,PERSON
.,O
Dexin,PERSON
Gong,PERSON
.,O
Guimin,PERSON
Chen,PERSON
.,O
Moran,PERSON
Dong,PERSON
&,O
Wenjun,PERSON
Ma,PERSON
(,O
2020,DATE
),O
:,O
Risk,O
factors,O
associated,O
with,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
:,O
a,O
retro,O
‐,O
spective,O
cohort,O
study,O
based,O
on,O
contacts,O
tracing,O
.,O
Emerging,O
Mi,O
‐,O
crobes,O
&,O
UK,COUNTRY
Limited,O
.,O
trading,O
as,O
Taylor,ORGANIZATION
&,ORGANIZATION
Francis,ORGANIZATION
Group,ORGANIZATION
.,O
on,O
behalf,O
of,O
Shanghai,ORGANIZATION
Shangyixun,ORGANIZATION
Cultural,ORGANIZATION
Communication,ORGANIZATION
Co.,ORGANIZATION
.,O
Ltd,O
View,O
sup,O
‐,O
plementary,O
material,O
View,O
Crossmark,O
data,O
Full,O
Terms,O
&,O
Conditions,O
of,O
access,O
and,O
use,O
can,O
be,O
found,O
at,O
Taylor,ORGANIZATION
&,ORGANIZATION
Francis,ORGANIZATION
Group,ORGANIZATION
.,O
on,O
be,O
‐,O
half,O
of,O
Shanghai,ORGANIZATION
Shangyixun,ORGANIZATION
Cultural,ORGANIZATION
Communication,ORGANIZATION
Co.,ORGANIZATION
.,O
Ltd,PERSON
Risk,PERSON
factors,O
associated,O
with,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
:,O
a,O
retrospective,O
co,O
‐,O
hort,O
study,O
based,O
on,O
contacts,O
tracing,O
Tao,O
Liu1,O
*,O
.,O
Wenjia,O
Liang2,O
*,O
.,O
Haojie,O
Zhong2,O
*,O
.,O
Jianfeng,PERSON
He2,O
*,O
.,O
Zihui,O
Chen1,O
*,O
.,O
Guanhao,O
He1,O
*,O
.,O
Tie,O
Song2,O
.,O
Shaowei,O
Chen1,O
.,O
Ping,O
Wang1,O
.,O
Jialing,O
Li2,O
.,O
Yunhua,O
Lan2,O
.,O
Mingji,O
Cheng2,O
.,O
Jinxu,PERSON
Huang2,PERSON
.,O
Jiwei,PERSON
Niu2,O
.,O
Liang,PERSON
Xia2,PERSON
.,O
Jianpeng,PERSON
Xi,PERSON
‐,PERSON
ao1,O
.,O
Jianxiong,PERSON
Hu1,PERSON
.,O
Lifeng,PERSON
Lin2,PERSON
.,O
Qiong,PERSON
Huang2,PERSON
.,O
Zuhua,PERSON
Rong1,PERSON
.,O
Aip,PERSON
‐,PERSON
ing,O
Deng2,O
.,O
Weilin,PERSON
Zeng1,PERSON
.,O
Jiansen,PERSON
Li2,PERSON
.,O
Xing,PERSON
Li1,PERSON
.,O
Xiaohua,PERSON
Tan2,PERSON
.,O
Min,DURATION
Kang2,O
.,O
Lingchuan,PERSON
Guo1,PERSON
.,O
Zhihua,PERSON
Zhu1,PERSON
.,O
Dexin,PERSON
Gong1,PERSON
.,O
Guimin,O
Chen1,O
.,O
Moran,PERSON
Dong1,O
.,O
Wenjun,ORGANIZATION
Ma1,ORGANIZATION
Control,ORGANIZATION
and,ORGANIZATION
Prevention,ORGANIZATION
.,O
Guangzhou,CITY
.,O
China,COUNTRY
.,O
2,NUMBER
.,O
Guangdong,ORGANIZATION
Provincial,ORGANIZATION
Center,ORGANIZATION
for,ORGANIZATION
Disease,ORGANIZATION
Control,ORGANIZATION
and,O
Preven,O
‐,O
tion,O
.,O
Guangzhou,CITY
.,O
China,COUNTRY
.,O
Correspondence,O
to,O
:,O
Disease,CAUSE_OF_DEATH
Control,O
and,O
Prevention,O
.,O
Guangzhou,CITY
511430,NUMBER
.,O
China,COUNTRY
Running,O
title,O
:,O
Risk,O
factors,O
of,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
.,O
Total,O
word,O
count,TITLE
:,O
4941,NUMBER
Objectives,O
To,O
es,O
‐,O
timate,O
the,O
attack,CAUSE_OF_DEATH
rates,O
.,O
and,O
identify,O
the,O
risk,O
factors,O
of,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
.,O
Methods,O
Based,O
on,O
a,O
retrospective,O
cohort,O
study,O
.,O
we,O
investigated,O
11.580,NUMBER
contacts,O
of,O
COVID,O
‐,O
19,NUMBER
cases,O
in,O
Guangdong,STATE_OR_PROVINCE
Province,LOCATION
from,O
January,DATE
10,DATE
to,O
March,DATE
15,DATE
.,DATE
2020,DATE
.,O
All,O
con,O
‐,O
tacts,O
were,O
tested,O
by,O
RT,O
‐,O
PCR,O
to,O
detect,O
their,O
infection,CAUSE_OF_DEATH
of,O
SARS,O
‐,O
COV,O
‐,O
2,NUMBER
.,O
Attack,CAUSE_OF_DEATH
rates,O
by,O
characteristics,O
were,O
calculated,O
.,O
and,O
lo,O
‐,O
gistic,O
regression,O
was,O
used,O
to,O
estimate,O
the,O
risk,O
factors,O
of,O
infec,O
‐,O
tion,O
for,O
COVID,O
‐,O
19,NUMBER
.,O
Results,O
A,O
total,O
of,O
515,NUMBER
of,O
11.580,NUMBER
contacts,O
were,O
identified,O
to,O
be,O
infected,O
with,O
SARS,O
‐,O
COV,O
‐,O
2,NUMBER
.,O
Compared,O
to,O
young,O
adults,O
aged,O
20,NUMBER
‐,O
29,DURATION
years,DURATION
.,O
the,O
infected,O
risk,O
was,O
higher,O
in,O
children,O
(,O
RR,O
:,O
2.59,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.79,NUMBER
‐,O
3.76,NUMBER
),O
.,O
and,O
old,O
people,O
aged,O
60,NUMBER
‐,O
69,NUMBER
years,DURATION
(,O
RR,O
:,O
5.29,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
3.76,NUMBER
‐,O
7.46,NUMBER
),O
.,O
Females,O
also,O
had,O
higher,O
in,O
‐,O
fected,O
risk,O
(,O
RR,O
:,O
1.66,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.39,NUMBER
‐,O
2.00,NUMBER
),O
.,O
People,O
having,O
close,O
re,O
‐,O
lationship,O
with,O
index,O
cases,O
encountered,O
higher,O
risk,O
to,O
be,O
infect,O
‐,O
ed,O
(,O
RR,O
for,O
spouse,O
:,O
20.68,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
14.28,NUMBER
‐,O
29.95,NUMBER
;,O
RR,O
for,O
non,O
‐,O
spouse,O
family,O
members,O
:,O
9.55,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
6.73,NUMBER
‐,O
13.55,NUMBER
;,O
RR,O
for,O
close,O
relatives,O
:,O
5.90,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
4.068.59,NUMBER
;,O
RR,O
for,O
other,O
relatives,O
:,O
3.37,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
2.15,NUMBER
‐,O
5.28,NUMBER
),O
.,O
Moreover,O
.,O
contacts,O
exposed,O
to,O
index,O
case,O
in,O
sympto,O
‐,O
matic,O
period,O
(,O
RR,O
:,O
2.15,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.67,NUMBER
‐,O
2.79,NUMBER
),O
.,O
with,O
critically,O
severe,O
symptoms,O
(,O
RR,O
:,O
1.61,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.00,NUMBER
‐,O
2.57,NUMBER
),O
.,O
with,O
symptoms,O
of,O
dizzy,O
(,O
RR,O
:,O
1.58,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.08,NUMBER
‐,O
2.30,NUMBER
),O
.,O
myalgia,O
(,O
RR,O
:,O
1.49,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.15,NUMBER
‐,O
1.94,NUMBER
),O
.,O
and,O
chill,O
(,O
RR,O
:,O
1.42,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.05,NUMBER
‐,O
1.92,NUMBER
),O
had,O
higher,O
in,O
‐,O
fected,O
risks,O
.,O
Conclusion,O
Children,O
.,O
old,O
people,O
.,O
females,O
and,O
fami,O
‐,O
ly,O
members,O
are,O
susceptible,O
to,O
be,O
infected,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
while,O
index,O
cases,O
in,O
incubation,O
period,O
had,O
lower,O
contagiousness,O
.,O
Our,O
findings,O
will,O
be,O
helpful,O
for,O
developing,O
targeted,O
prevention,O
and,O
control,O
strategies,O
to,O
combat,O
the,O
worldwide,O
pandemic,O
.,O
Key,O
words,O
:,O
COVID,O
‐,O
19,NUMBER
;,O
attack,CAUSE_OF_DEATH
rate,O
;,O
risk,O
factors,O
;,O
close,O
contact,O
;,O
China,COUNTRY
Since,O
the,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
outbreak,O
on,O
31,DATE
December,DATE
.,O
2019,DATE
[,O
1,NUMBER
],O
.,O
it,O
has,O
hit,O
more,O
than,O
200,NUMBER
countries,O
.,O
areas,O
or,O
territo,O
‐,O
ries,O
with,O
8.525.042,NUMBER
cases,O
and,O
456.973,NUMBER
deaths,O
as,O
of,O
June,DATE
20,DATE
.,DATE
2020,DATE
[,O
2,NUMBER
],O
.,O
World,ORGANIZATION
Health,ORGANIZATION
Organization,ORGANIZATION
(,O
WHO,O
),O
has,O
declared,O
COVID,O
‐,O
19,NUMBER
as,O
a,O
pandemic,O
on,O
March,DATE
11.2020,DATE
[,O
3,NUMBER
],O
.,O
Owing,O
to,O
the,O
effective,O
measure,O
taken,O
in,O
China,COUNTRY
.,O
the,O
chain,O
of,O
transmission,O
has,O
been,O
broken,O
and,O
the,O
epidemic,O
has,O
been,O
under,O
control,O
.,O
Contact,O
tracing,O
is,O
a,O
major,O
pub,O
‐,O
lic,O
health,O
response,O
to,O
imports,O
of,O
rare,O
or,O
emerging,O
infectious,O
diseases,CAUSE_OF_DEATH
.,O
The,O
main,O
objectives,O
of,O
contact,O
tracing,O
are,O
to,O
identify,O
potentially,O
infected,O
individuals,O
before,O
onset,O
of,O
severe,O
symptoms,O
.,O
and,O
to,O
prevent,O
onward,O
transmission,O
from,O
the,O
secondary,O
cases,O
.,O
Con,O
‐,O
tact,O
tracing,O
has,O
decisively,O
contributed,O
to,O
the,O
control,O
of,O
many,O
infectious,O
diseases,CAUSE_OF_DEATH
worldwide,O
including,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,MISC
),O
.,O
Ebola,MISC
virus,O
disease,CAUSE_OF_DEATH
.,O
and,O
Middle,LOCATION
East,LOCATION
respiratory,O
syndrome,O
(,O
MERS,O
),O
[,O
4,NUMBER
‐,O
7,NUMBER
],O
.,O
Report,O
of,O
the,O
WHO,O
‐,O
China,COUNTRY
Joint,O
Mission,O
on,O
COVID,O
‐,O
19,NUMBER
pointed,O
out,O
that,O
China,COUNTRY
has,O
a,O
policy,O
of,O
meticulous,O
case,O
and,O
contact,O
identification,O
for,O
COVID,O
‐,O
19,NUMBER
[,O
8,NUMBER
],O
.,O
Previous,O
studies,O
us,O
‐,O
ing,O
mathematical,O
modeling,O
also,O
theoretically,O
demonstrated,O
that,O
contact,O
tracing,O
and,O
quarantine,O
play,O
important,O
roles,O
in,O
control,O
‐,O
ling,O
the,O
spreading,O
of,O
COVID,O
‐,O
19,NUMBER
[,O
9.10,NUMBER
],O
.,O
In,O
addition,O
to,O
this,O
.,O
con,O
‐,O
tact,O
tracing,O
also,O
provides,O
a,O
unique,O
opportunity,O
to,O
investigate,O
the,O
epidemiological,O
features,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
Previous,O
researches,O
have,O
analyzed,O
the,O
data,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
and,O
found,O
some,O
risk,O
factors,O
of,O
mortality,O
.,O
such,O
as,O
older,O
age,O
.,O
pre,O
‐,O
existing,O
cardiovas,O
‐,O
cular,O
or,O
cerebrovascular,O
diseases,CAUSE_OF_DEATH
.,O
low,O
levels,O
of,O
CD3,O
+,O
CD8,O
+,O
T,O
‐,O
cells,O
.,O
high,O
levels,O
of,O
cardiac,O
troponin,O
I,O
.,O
higher,O
Sequential,O
Organ,O
Failure,O
Assessment,O
score,O
and,O
d,O
‐,O
dimer,O
[,O
11.12,NUMBER
],O
.,O
Unfortunately,O
.,O
lim,O
‐,O
ited,O
study,O
has,O
paid,O
attention,O
to,O
the,O
risk,O
factors,O
related,O
to,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
.,O
Recent,O
studies,O
conducted,O
among,O
1.286,NUMBER
close,O
contacts,O
(,O
98,NUMBER
of,O
them,O
were,O
infected,O
by,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
in,O
Shenzhen,CITY
and,O
among,O
2098,DATE
close,O
contacts,O
in,O
Guangzhou,CITY
(,O
134,NUMBER
of,O
them,O
were,O
infected,O
by,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
explored,O
the,O
risk,O
factors,O
for,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
.,O
like,O
older,O
age,O
.,O
travelling,O
to,O
Hubei,STATE_OR_PROVINCE
.,O
etc,O
[,O
13.14,NUMBER
],O
.,O
Another,O
recent,O
study,O
among,O
2761,DATE
close,O
contact,O
of,O
100,NUMBER
selected,O
index,O
cases,O
in,O
Taiwan,COUNTRY
identified,O
exposure,O
to,O
index,O
case,O
with,O
severe,O
symptoms,O
as,O
a,O
risk,O
factor,O
[,O
15,NUMBER
],O
.,O
However,O
.,O
their,O
limited,O
sample,O
size,O
.,O
espe,O
‐,O
cially,O
the,O
limited,O
cases,O
.,O
may,O
restrict,O
their,O
ability,O
to,O
perform,O
detailed,O
analysis,O
.,O
and,O
reduce,O
the,O
power,O
to,O
detect,O
significant,O
risk,O
factors,O
.,O
Additionally,O
.,O
findings,O
within,O
a,O
single,O
city,O
or,O
se,O
‐,O
lected,O
sample,O
may,O
restrict,O
its,O
ability,O
of,O
generalization,O
.,O
In,O
the,O
current,DATE
study,O
.,O
we,O
employed,O
a,O
large,O
dataset,O
including,O
11.686,NUMBER
close,O
contacts,O
of,O
COVID,O
‐,O
19,NUMBER
cases,O
(,O
449,NUMBER
of,O
them,O
were,O
infected,O
),O
in,O
Guang,LOCATION
‐,O
dong,O
Province,O
.,O
China,COUNTRY
to,O
estimate,O
the,O
attack,CAUSE_OF_DEATH
rates,O
.,O
and,O
identify,O
risk,O
factors,O
for,O
infection,CAUSE_OF_DEATH
of,O
COVID,O
‐,O
19,NUMBER
.,O
Under,O
the,O
context,O
of,O
worldwide,O
pandemic,O
.,O
understanding,O
this,O
issue,O
can,O
identify,O
high,O
‐,O
risk,O
groups,O
and,O
provide,O
evidence,O
to,O
develop,O
targeted,O
Setting,O
and,O
definitions,O
Guangdong,STATE_OR_PROVINCE
.,O
a,O
province,O
with,O
large,O
population,O
size,O
lo,O
‐,O
cated,O
in,O
Southern,LOCATION
China,COUNTRY
.,O
is,O
a,O
place,O
early,O
affected,O
by,O
COVID,O
‐,O
19,NUMBER
.,O
The,O
first,ORDINAL
confirmed,O
case,O
was,O
reported,O
on,O
January,DATE
15,DATE
.,DATE
2020,DATE
.,O
and,O
a,O
total,O
of,O
1.361,NUMBER
confirmed,O
cases,O
were,O
reported,O
by,O
March,DATE
15,DATE
.,DATE
2020,DATE
.,O
Since,O
the,O
very,O
early,O
stage,O
of,O
COVID,O
‐,O
19,NUMBER
outbreak,O
.,O
an,O
intensified,O
surveillance,O
was,O
implemented,O
across,O
Guangdong,STATE_OR_PROVINCE
Province,LOCATION
to,O
detect,O
suspected,O
and,O
confirmed,O
COVID,O
‐,O
19,NUMBER
cases,O
.,O
and,O
their,O
close,O
contacts,O
following,O
standardized,O
protocols,O
released,O
by,O
the,O
National,O
Health,O
Commission,O
of,O
China,COUNTRY
.,O
Suspected,O
and,O
confirmed,O
COVID19,O
cases,O
were,O
defined,O
based,O
on,O
the,O
Diagnosis,MISC
and,O
Treatment,O
scheme,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
and,O
close,O
contacts,O
were,O
defined,O
by,O
the,O
Prevention,O
and,O
Control,O
Scheme,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
These,O
two,NUMBER
schemes,O
Identification,O
and,O
quaran,O
‐,O
tine,O
of,O
contacts,O
Once,DATE
a,O
suspected,O
or,O
confirmed,O
COVID,O
‐,O
19,NUMBER
case,O
was,O
identified,O
.,O
the,O
case,O
would,O
be,O
reported,O
as,O
an,O
index,O
case,O
and,O
iso,O
‐,O
lated,O
.,O
and,O
the,O
Center,ORGANIZATION
for,ORGANIZATION
Diseases,ORGANIZATION
Control,ORGANIZATION
and,ORGANIZATION
Prevention,ORGANIZATION
(,O
CDC,ORGANIZATION
),O
will,O
conduct,O
a,O
field,O
investigation,O
.,O
Information,O
of,O
index,O
cases,O
was,O
collected,O
by,O
clinical,O
workers,O
.,O
including,O
demographic,O
informa,O
‐,O
tion,O
.,O
exposure,O
history,O
.,O
clinical,O
symptoms,O
.,O
date,O
of,O
symptom,O
onset,O
.,O
laboratory,O
test,O
results,O
.,O
and,O
the,O
severity,O
.,O
This,O
information,O
was,O
directly,O
reported,O
to,O
the,O
National,O
Internet,O
‐,O
Based,O
Infectious,O
Dis,O
‐,O
eases,O
Reporting,O
System,O
.,O
Information,O
of,O
contacts,O
was,O
collected,O
by,O
CDC,ORGANIZATION
using,O
a,O
standardized,O
questionnaire,O
.,O
including,O
general,TITLE
demo,O
‐,O
graphic,O
characteristics,O
.,O
relationships,O
with,O
the,O
index,O
case,O
.,O
and,O
patterns,O
and,O
frequency,O
of,O
contract,O
.,O
Meanwhile,O
.,O
their,O
throat,O
swabs,O
were,O
collected,O
and,O
detected,O
by,O
real,O
‐,O
time,O
reverse,O
transcriptase,O
polymerase,O
chain,O
reaction,O
assay,O
(,O
RT,O
‐,O
PCR,O
),O
.,O
During,O
the,O
quarantine,O
.,O
health,O
status,O
of,O
all,O
contacts,O
was,O
monitored,O
.,O
and,O
their,O
throat,O
swabs,O
were,O
collected,O
every,SET
several,SET
days,SET
to,O
test,O
their,O
infection,CAUSE_OF_DEATH
status,O
.,O
Once,DATE
they,O
were,O
identified,O
with,O
positive,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARS,O
‐,O
COV,O
‐,O
2,NUMBER
),O
.,O
they,O
would,O
be,O
transferred,O
to,O
a,O
designated,O
hospital,O
for,O
diagnosis,O
and,O
treatment,O
.,O
Clinical,O
symptoms,O
and,O
severity,O
of,O
these,O
infected,O
contacts,O
were,O
followed,O
up,O
and,O
recorded,O
by,O
clinical,O
workers,O
.,O
After,O
14,DURATION
days,DURATION
quar,O
‐,O
antine,O
.,O
contacts,O
with,O
negative,O
SARS,O
‐,O
COV,O
‐,O
2,NUMBER
were,O
released,O
.,O
Statis,O
‐,O
tical,O
analysis,O
Categorical,O
variables,O
were,O
described,O
using,O
per,O
‐,O
centage,O
(,O
%,O
),O
.,O
and,O
a,O
Chi,O
‐,O
square,O
test,O
was,O
used,O
to,O
test,O
the,O
differ,O
‐,O
ences,O
in,O
distributions,O
of,O
categorical,O
variables,O
between,O
index,O
and,O
secondary,O
cases,O
.,O
If,O
conditions,O
for,O
Chi,O
‐,O
square,O
test,O
were,O
not,O
sat,O
‐,O
isfied,O
.,O
Fishers,O
exact,O
test,O
was,O
used,O
.,O
Attack,CAUSE_OF_DEATH
rate,O
was,O
calculated,O
as,O
the,O
percentage,O
of,O
contacts,O
who,O
were,O
later,O
confirmed,O
to,O
be,O
in,O
‐,O
fected,O
with,O
SARS,O
‐,O
COV,O
‐,O
2,NUMBER
.,O
We,O
estimated,O
the,O
attack,CAUSE_OF_DEATH
rates,O
of,O
contacts,O
by,O
gender,O
.,O
age,O
.,O
relationships,O
to,O
index,O
cases,O
(,O
household,O
members,O
.,O
relatives,O
.,O
social,O
activities,O
.,O
etc.,O
),O
.,O
transportations,O
(,O
flight,O
.,O
train,CRIMINAL_CHARGE
.,O
public,O
transportation,O
.,O
provide,O
car,O
.,O
and,O
the,O
Dream,O
Cruise,O
),O
where,O
infection,CAUSE_OF_DEATH
occurred,O
.,O
course,O
of,O
disease,CAUSE_OF_DEATH
(,O
incubation,O
period,O
.,O
symptomatic,O
period,O
.,O
and,O
different,O
days,DURATION
from,O
symptom,O
onset,O
),O
of,O
in,O
‐,O
dex,O
cases,O
when,O
the,O
contact,O
occurred,O
.,O
severity,O
of,O
index,O
cases,O
(,O
mild,O
.,O
moderate,O
.,O
severe,O
.,O
and,O
critically,O
severe,O
),O
.,O
and,O
clinical,O
symptoms,O
of,O
index,O
cases,O
.,O
These,O
attack,CAUSE_OF_DEATH
rates,O
were,O
calculated,O
only,O
using,O
sub,O
‐,O
datasets,O
of,O
the,O
index,O
cases,O
and,O
contacts,O
with,O
detailed,O
information,O
because,O
some,O
cases,O
had,O
no,O
complete,O
information,O
for,O
estimate,O
.,O
Logistic,MISC
regression,O
was,O
also,O
conducted,O
to,O
estimate,O
the,O
risk,O
factors,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
All,O
data,O
analyses,O
were,O
conducted,O
by,O
R,O
software,O
(,O
version,O
3.5.0,NUMBER
.,O
R,ORGANIZATION
Foundation,ORGANIZATION
for,ORGANIZATION
Statistical,ORGANIZATION
Computing,ORGANIZATION
),O
.,O
General,TITLE
characteristics,O
of,O
contacts,O
As,O
of,O
March,DATE
15,DATE
.,DATE
2020,DATE
.,O
a,O
total,O
of,O
11.686,NUMBER
contacts,O
were,O
traced,O
and,O
quarantined,O
.,O
The,O
first,ORDINAL
contact,O
was,O
identified,O
on,O
January,DATE
10,DATE
.,DATE
2020,DATE
.,O
Contacts,O
(,O
n,O
=,O
106,NUMBER
),O
without,O
key,O
formation,O
were,O
excluded,O
.,O
and,O
11.580,NUMBER
contacts,O
.,O
which,O
peaked,O
(,O
n,O
=,O
574,NUMBER
),O
on,O
January,DATE
31,DATE
.,O
Of,O
total,O
contacts,O
.,O
6.183,NUMBER
(,O
53.4,PERCENT
%,PERCENT
),O
were,O
males,O
;,O
8.419,NUMBER
(,O
72.7,PERCENT
%,PERCENT
),O
were,O
adults,O
aged,O
20,NUMBER
‐,O
59,DURATION
years,DURATION
.,O
and,O
9.725,NUMBER
(,O
84.0,PERCENT
%,PERCENT
),O
contacts,O
were,O
quarantined,O
in,O
centralized,O
stations,O
.,O
The,O
number,O
of,O
contacts,O
occurred,O
at,O
home,O
.,O
in,O
social,O
activities,O
.,O
on,O
transportations,O
.,O
and,O
in,O
health,O
care,O
settings,O
were,O
4.893,NUMBER
(,O
41.0,PERCENT
%,PERCENT
),O
.,O
2.016,NUMBER
(,O
16.9,PERCENT
%,PERCENT
),O
.,O
3.198,NUMBER
(,O
26.5,PERCENT
%,PERCENT
),O
and,O
1.348,NUMBER
(,O
11.3,PERCENT
%,PERCENT
),O
.,O
respectively,O
.,O
Many,O
contacts,O
were,O
from,O
family,O
members,O
of,O
index,O
cases,O
(,O
4.707,NUMBER
.,O
40.7,PERCENT
%,PERCENT
),O
.,O
social,O
activity,O
contacts,O
(,O
3.344,NUMBER
.,O
28.9,PERCENT
%,PERCENT
),O
.,O
transportation,O
contacts,O
(,O
2.778,NUMBER
.,O
24.0,PERCENT
%,PERCENT
),O
.,O
and,O
health,O
care,O
workers,O
7.0,NUMBER
‐,O
8.7,NUMBER
),O
close,O
contacts,O
per,O
index,O
case,O
.,O
The,O
average,O
contacts,O
per,O
index,O
case,O
var,O
‐,O
ied,O
with,O
contact,O
quarantine,O
was,O
6.4,DURATION
days,DURATION
.,O
and,O
the,O
average,O
dura,O
‐,O
tion,O
of,O
quarantine,O
was,O
9.7,DURATION
days,DURATION
.,O
Attack,CAUSE_OF_DEATH
rates,O
of,O
COVID,O
‐,O
19,NUMBER
Until,O
March,DATE
15,DATE
.,O
515,NUMBER
(,O
4.4,PERCENT
%,PERCENT
),O
contacts,O
were,O
identified,O
to,O
be,O
infected,O
with,O
SARS,O
‐,O
COV,O
‐,O
2,NUMBER
.,O
The,O
attack,CAUSE_OF_DEATH
rates,O
varied,O
by,O
age,O
groups,O
with,O
the,O
high,O
‐,O
est,O
for,O
the,O
group,O
aged,O
60,NUMBER
‐,O
69,DURATION
years,DURATION
(,O
11.1,PERCENT
%,PERCENT
),O
.,O
and,O
the,O
lowest,O
for,O
the,O
group,O
of,O
20,NUMBER
‐,O
29,DURATION
years,DURATION
(,O
2.3,PERCENT
%,PERCENT
),O
.,O
The,O
attack,CAUSE_OF_DEATH
rate,O
of,O
children,O
<,O
10,NUMBER
years,DURATION
was,O
5.7,PERCENT
%,PERCENT
.,O
and,O
the,O
attack,CAUSE_OF_DEATH
rates,O
were,O
higher,O
in,O
children,O
whose,O
index,O
cases,O
aged,O
30,NUMBER
‐,O
39,DURATION
years,DURATION
(,O
8.5,PERCENT
%,PERCENT
),O
.,O
and,O
50,NUMBER
‐,O
59,DURATION
years,DURATION
(,O
7.0,PERCENT
%,PERCENT
),O
We,O
also,O
observed,O
a,O
higher,O
attack,CAUSE_OF_DEATH
rate,O
in,O
females,O
(,O
5.6,PERCENT
%,PERCENT
),O
than,O
in,O
males,O
(,O
3.5,PERCENT
%,PERCENT
),O
.,O
In,O
addition,O
.,O
contacts,O
having,O
close,O
relationship,O
with,O
index,O
cases,O
had,O
higher,O
attack,CAUSE_OF_DEATH
rate,O
(,O
attack,CAUSE_OF_DEATH
rate,O
:,O
23.3,PERCENT
%,PERCENT
for,O
spouse,O
;,O
10.6,PERCENT
%,PERCENT
for,O
non,O
‐,O
spouse,O
family,O
members,O
;,O
7.0,PERCENT
%,PERCENT
for,O
close,O
rela,O
‐,O
tives,O
;,O
4.1,PERCENT
%,PERCENT
for,O
other,O
relatives,O
.,O
1.3,PERCENT
%,PERCENT
for,O
social,O
activity,O
con,O
‐,O
tacts,O
.,O
etc.,O
),O
.,O
Different,O
attack,CAUSE_OF_DEATH
rates,O
also,O
occurred,O
in,O
various,O
transportations,O
where,O
infection,CAUSE_OF_DEATH
occurred,O
.,O
Attack,CAUSE_OF_DEATH
rates,O
were,O
0.8,PERCENT
%,PERCENT
on,O
flight,O
.,O
1.2,PERCENT
%,PERCENT
on,O
train,CRIMINAL_CHARGE
.,O
2.1,PERCENT
%,PERCENT
on,O
public,O
transportation,O
.,O
4.2,PERCENT
%,PERCENT
on,O
private,O
car,O
and,O
9.4,PERCENT
%,PERCENT
on,O
the,O
Dream,O
Cruise,O
(,O
9.4,PERCENT
%,PERCENT
),O
.,O
When,O
consider,O
‐,O
ing,O
the,O
time,O
contacting,O
with,O
the,O
index,O
cases,O
.,O
attack,CAUSE_OF_DEATH
rates,O
were,O
3.3,PERCENT
%,PERCENT
and,O
7.0,PERCENT
%,PERCENT
when,O
contacts,O
occurred,O
in,O
the,O
index,O
cases,O
incuba,O
‐,O
tion,O
period,O
and,O
symptomatic,O
period,O
.,O
In,O
detail,O
.,O
attack,CAUSE_OF_DEATH
rate,O
in,O
‐,O
creased,O
from,O
five,DURATION
days,DURATION
prior,O
to,O
the,O
symptom,O
onset,O
of,O
index,O
cases,O
(,O
1.7,PERCENT
%,PERCENT
),O
.,O
to,O
a,O
peak,O
during,O
34,DURATION
days,DURATION
(,O
10.1,PERCENT
%,PERCENT
),O
after,O
onset,O
.,O
and,O
then,O
decreased,O
to,O
4.0,PERCENT
%,PERCENT
after,O
17,DURATION
days,DURATION
of,O
the,O
onset,O
.,O
In,O
addition,O
.,O
attack,CAUSE_OF_DEATH
rates,O
increased,O
from,O
4.6,PERCENT
%,PERCENT
for,O
the,O
contacts,O
of,O
mild,O
cases,O
to,O
7.5,PERCENT
%,PERCENT
for,O
the,O
contacts,O
of,O
critically,O
severe,O
and,O
higher,O
attack,CAUSE_OF_DEATH
rates,O
were,O
observed,O
in,O
index,O
cases,O
with,O
dyspnea,O
(,O
11.2,PERCENT
%,PERCENT
),O
.,O
dizzy,O
(,O
10.6,PERCENT
%,PERCENT
),O
.,O
muscle,O
soreness,O
(,O
10.4,PERCENT
%,PERCENT
),O
.,O
and,O
shortness,O
of,O
breath,O
(,O
10.0,PERCENT
%,PERCENT
),O
.,O
Risk,O
of,O
infection,CAUSE_OF_DEATH
for,O
COVID,O
‐,O
19,NUMBER
Compared,O
with,O
people,O
aged,O
20,NUMBER
‐,O
29,DURATION
years,DURATION
.,O
children,O
<,O
10,DURATION
years,DURATION
(,O
RR,O
:,O
2.59,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.79,NUMBER
‐,O
3.76,NUMBER
),O
and,O
children,O
aged,O
10,NUMBER
‐,O
19,NUMBER
(,O
RR,O
:,O
1.81,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.17,NUMBER
‐,O
2.81,NUMBER
),O
had,O
higher,O
risk,O
to,O
be,O
infected,O
with,O
COVID,O
‐,O
19,NUMBER
50,NUMBER
‐,O
59,DURATION
years,DURATION
(,O
RR,O
:,O
2.30,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.65,NUMBER
‐,O
3.27,NUMBER
),O
.,O
60,NUMBER
‐,O
69,NUMBER
years,DURATION
(,O
RR,O
:,O
5.29,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
3.76,NUMBER
‐,O
7.46,NUMBER
),O
and,O
70,NUMBER
‐,O
79,DURATION
years,DURATION
(,O
RR,O
:,O
3.03,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.81,NUMBER
‐,O
5.08,NUMBER
),O
.,O
Moreover,O
.,O
young,O
adults,O
(,O
aged,O
30,NUMBER
‐,O
39,DURATION
years,DURATION
),O
.,O
whose,O
index,O
cases,O
having,O
close,O
relationship,O
with,O
index,O
cases,O
en,O
‐,O
countered,O
higher,O
risk,O
to,O
be,O
infected,O
(,O
RR,O
and,O
95,PERCENT
%,PERCENT
CI,O
:,O
20.68,NUMBER
[,O
14.28,NUMBER
‐,O
29.95,NUMBER
],O
for,O
spouse,O
;,O
9.55,NUMBER
[,O
6.73,NUMBER
‐,O
13.55,NUMBER
],O
for,O
non,O
‐,O
spouse,O
family,O
members,O
;,O
5.90,NUMBER
[,O
4.06,NUMBER
‐,O
8.59,NUMBER
],O
transportations,O
.,O
we,O
did,O
not,O
observe,O
significant,O
difference,O
across,O
various,O
transportations,O
except,O
in,O
When,O
considering,O
time,O
contacting,O
with,O
index,O
cases,O
.,O
the,O
risk,O
of,O
exposure,O
to,O
index,O
cases,O
in,O
the,O
2E,O
),O
.,O
More,O
specifically,O
.,O
the,O
in,O
‐,O
fected,O
risk,O
increased,O
from,O
five,NUMBER
plus,O
days,DURATION
prior,O
to,O
the,O
symptom,O
onset,O
2F,O
),O
.,O
Moreover,O
.,O
contact,O
with,O
index,O
cases,O
with,O
critically,O
se,O
‐,O
vere,O
symptoms,O
was,O
associated,O
with,O
a,O
for,O
the,O
contacts,O
of,O
index,O
cases,O
with,O
different,O
clinical,O
symptoms,O
compared,O
to,O
fever,CAUSE_OF_DEATH
.,O
and,O
there,O
were,O
higher,O
risks,O
in,O
index,O
cases,O
with,O
dizzy,O
(,O
RR,O
:,O
1.58,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.08,NUMBER
‐,O
2.30,NUMBER
),O
.,O
myalgia,O
(,O
RR,O
:,O
1.49,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.15,NUMBER
‐,O
1.94,NUMBER
),O
.,O
and,O
chill,O
(,O
RR,O
:,O
1.42,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
:,O
1.05,NUMBER
‐,O
1.92,NUMBER
),O
.,O
After,O
reporting,O
the,O
first,ORDINAL
case,O
on,O
January,DATE
15,DATE
.,DATE
2020,DATE
.,O
Guangdong,STATE_OR_PROVINCE
Provincial,O
government,O
mobi,O
‐,O
lized,O
enormous,O
resources,O
to,O
respond,O
to,O
the,O
COVID,O
‐,O
19,NUMBER
epidemic,O
.,O
More,O
than,O
11.000,NUMBER
close,O
contacts,O
of,O
COVID,O
‐,O
19,NUMBER
were,O
traced,O
and,O
quar,O
‐,O
antined,O
.,O
One,NUMBER
third,ORDINAL
of,O
the,O
total,O
cases,O
reported,O
in,O
Guangdong,STATE_OR_PROVINCE
Prov,O
‐,O
ince,O
were,O
identified,O
from,O
these,O
contacts,O
.,O
which,O
indicate,O
that,O
contact,O
tracing,O
strategy,O
have,O
played,O
an,O
important,O
role,O
in,O
con,O
‐,O
taining,O
the,O
spreading,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
The,O
analysis,O
of,O
index,O
cases,O
and,O
their,O
close,O
contacts,O
provides,O
insight,O
into,O
the,O
attack,CAUSE_OF_DEATH
rates,O
and,O
risk,O
factors,O
of,O
infection,CAUSE_OF_DEATH
for,O
COVID19,O
.,O
We,O
found,O
that,O
attack,CAUSE_OF_DEATH
rates,O
were,O
higher,O
in,O
the,O
elderly,O
with,O
the,O
highest,O
in,O
the,O
group,O
aged,O
60,NUMBER
‐,O
69,DURATION
years,DURATION
.,O
and,O
logistic,O
regression,O
demonstrated,O
the,O
sta,O
‐,O
tistical,O
significance,O
.,O
These,O
findings,O
are,O
consistent,O
with,O
the,O
re,O
‐,O
sults,O
for,O
SARS,O
in,O
Beijing,CITY
[,O
7,NUMBER
],O
.,O
Recent,O
studies,O
also,O
reported,O
that,O
elderly,O
contacts,O
were,O
more,O
observe,O
significant,O
higher,O
infected,O
risk,O
of,O
elderly,O
contacts,O
.,O
which,O
may,O
ascribe,O
its,O
insufficient,O
sam,O
‐,O
ple,O
size,O
[,O
15,NUMBER
],O
.,O
Our,O
findings,O
thus,O
confirmed,O
greater,O
vulnerability,O
of,O
the,O
elderly,O
.,O
Those,O
contacts,O
aged,O
6069,DURATION
years,DURATION
could,O
have,O
more,O
physical,O
activities,O
than,O
older,O
people,O
.,O
which,O
may,O
cause,O
closer,O
contact,O
with,O
index,O
case,O
for,O
a,O
longer,O
period,O
[,O
7,NUMBER
],O
.,O
Meanwhile,O
.,O
the,O
immunity,O
of,O
the,O
age,O
may,O
be,O
weaker,O
than,O
younger,O
adults,O
.,O
making,O
them,O
more,O
susceptible,O
to,O
infection,CAUSE_OF_DEATH
.,O
Therefore,O
.,O
more,O
efforts,O
are,O
needed,O
to,O
protect,O
the,O
elderly,O
from,O
the,O
infection,CAUSE_OF_DEATH
of,O
COVID,O
‐,O
19,NUMBER
.,O
The,O
susceptibility,O
of,O
children,O
to,O
COVID,O
‐,O
19,NUMBER
is,O
controversial,O
[,O
8.18,NUMBER
],O
.,O
Clinical,O
data,O
of,O
COVID,O
‐,O
19,NUMBER
considering,O
literatures,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
children,O
pointed,O
out,O
that,O
children,O
cases,O
are,O
usually,O
less,O
severe,O
than,O
adult,O
cases,O
.,O
and,O
more,O
children,O
cases,O
are,O
asymp,O
‐,O
tomatic,O
infection,CAUSE_OF_DEATH
.,O
which,O
makes,O
them,O
less,O
opportunity,O
to,O
be,O
tested,O
and,O
identified,O
[,O
21,NUMBER
],O
.,O
However,O
.,O
we,O
found,O
higher,O
infected,O
risk,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
children,O
<,O
10,DURATION
years,DURATION
that,O
their,O
RR,O
were,O
larger,O
than,O
contacts,O
aged,O
10,NUMBER
‐,O
59,DURATION
years,DURATION
.,O
which,O
indicates,O
that,O
children,O
were,O
al,O
‐,O
so,O
susceptible,O
to,O
COVID,O
‐,O
19,NUMBER
.,O
Furthermore,O
.,O
we,O
observed,O
a,O
higher,O
at,O
‐,O
tack,O
rate,O
in,O
children,O
whose,O
index,O
cases,O
aged,O
30,NUMBER
‐,O
39,NUMBER
and,O
50,NUMBER
‐,O
59,NUMBER
years,DURATION
.,O
Although,O
limited,O
sample,O
size,O
may,O
cause,O
insignificant,O
RR,O
.,O
our,O
results,O
still,O
implicated,O
that,O
the,O
children,O
may,O
be,O
mainly,O
in,O
‐,O
fected,O
by,O
their,O
parents,O
and,O
grandparents,O
.,O
Two,NUMBER
recent,O
studies,O
re,O
‐,O
ported,O
consistent,O
results,O
with,O
our,O
study,O
[,O
13.22,NUMBER
],O
.,O
For,O
instance,O
.,O
Dong,PERSON
et,O
al.,O
analyzed,O
2.143,NUMBER
pediatric,O
COVID,O
‐,O
19,NUMBER
patients,O
across,O
China,COUNTRY
.,O
and,O
found,O
that,O
children,O
were,O
susceptible,O
to,O
COVID,O
‐,O
19,NUMBER
[,O
22,NUMBER
],O
.,O
Additionally,O
.,O
young,O
adults,O
(,O
30,NUMBER
‐,O
39,DURATION
years,DURATION
),O
were,O
more,O
likely,O
to,O
be,O
years,DURATION
.,O
These,O
findings,O
may,O
be,O
attributed,O
to,O
the,O
status,O
that,O
young,O
adults,O
are,O
the,O
primary,O
caregivers,O
once,DATE
their,O
children,O
and,O
parents,O
got,O
sick,O
.,O
and,O
they,O
are,O
also,O
the,O
individuals,O
who,O
have,O
many,O
social,O
protection,O
both,O
at,O
home,O
and,O
in,O
public,O
places,O
.,O
Compared,O
with,O
pre,O
‐,O
vious,O
studies,O
.,O
our,O
study,O
prospectively,O
collected,O
data,O
based,O
on,O
contacts,O
tracing,O
.,O
which,O
had,O
explicit,O
temporality,O
for,O
causal,O
in,O
‐,O
ference,O
and,O
reduced,O
recall,O
bias,O
.,O
and,O
therefore,O
provide,O
more,O
reli,O
‐,O
able,O
evidence,O
.,O
Our,O
finding,O
is,O
helpful,O
for,O
preventing,O
people,O
from,O
being,O
infected,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
We,O
observed,O
that,O
female,O
contacts,O
were,O
more,O
likely,O
to,O
be,O
infected,O
by,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
than,O
male,O
contacts,O
.,O
which,O
is,O
consistent,O
with,O
previous,O
studies,O
[,O
13.14,NUMBER
],O
.,O
For,O
example,O
.,O
a,O
recent,O
study,O
conducted,O
in,O
Guangzhou,CITY
also,O
found,O
higher,O
attack,CAUSE_OF_DEATH
rates,O
in,O
females,O
than,O
in,O
males,O
[,O
14,NUMBER
],O
.,O
This,O
difference,O
in,O
attack,CAUSE_OF_DEATH
rate,O
between,O
sex,O
may,O
be,O
due,O
to,O
several,O
reasons,O
:,O
(,O
1,NUMBER
),O
females,O
play,O
predominant,O
roles,O
as,O
caregivers,O
within,O
family,O
and,O
may,O
have,O
closer,O
contact,O
and,O
longer,O
contact,O
period,O
with,O
the,O
index,O
cases,O
[,O
23,NUMBER
],O
;,O
(,O
2,NUMBER
),O
females,O
comprise,O
a,O
large,O
proportion,O
of,O
health,O
‐,O
care,O
workers,O
[,O
24,NUMBER
],O
.,O
Therefore,O
.,O
our,O
findings,O
suggest,O
more,O
prevention,O
measures,O
specifi,O
‐,O
cally,O
implemented,O
to,O
protect,O
females,O
from,O
infection,CAUSE_OF_DEATH
during,O
the,O
epidemic,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
We,O
observed,O
that,O
the,O
relationships,O
between,O
contacts,O
and,O
index,O
cases,O
significantly,O
affected,O
the,O
infected,O
risks,O
.,O
Compared,O
with,O
the,O
social,O
activity,O
contacts,O
.,O
the,O
risk,O
of,O
being,O
infected,O
was,O
more,O
than,O
20,NUMBER
times,O
higher,O
among,O
the,O
spouse,O
and,O
more,O
than,O
9,NUMBER
times,O
higher,O
among,O
other,O
family,O
members,O
.,O
also,O
found,O
that,O
more,O
infections,CAUSE_OF_DEATH
were,O
acquired,O
in,O
household,O
[,O
15,NUMBER
],O
.,O
Family,O
mem,O
‐,O
bers,O
are,O
more,O
likely,O
to,O
have,O
closer,O
contact,O
with,O
index,O
case,O
for,O
a,O
longer,O
contact,O
period,O
with,O
shorter,O
distance,O
.,O
Another,O
possible,O
reason,O
is,O
that,O
family,O
members,O
may,O
have,O
some,O
certain,O
linkage,O
with,O
index,O
cases,O
in,O
living,O
habits,O
which,O
may,O
cause,O
higher,O
predisposi,O
‐,O
tion,O
in,O
infection,CAUSE_OF_DEATH
than,O
other,O
close,O
contacts,O
.,O
Unfortunately,O
.,O
indi,O
‐,O
viduals,O
commonly,O
take,O
protective,O
measures,O
in,O
public,O
place,O
like,O
washing,O
hands,O
and,O
wearing,O
mask,O
.,O
but,O
neglect,O
personal,O
protection,O
at,O
home,O
.,O
This,O
indicates,O
the,O
necessity,O
for,O
public,O
to,O
pay,O
attention,O
to,O
personal,O
protective,O
at,O
home,O
especially,O
when,O
family,O
members,O
de,O
‐,O
velop,O
symptom,O
or,O
have,O
travel,O
history,O
of,O
epidemic,O
areas,O
.,O
We,O
also,O
compared,O
attack,CAUSE_OF_DEATH
rates,O
occurred,O
on,O
different,O
transportations,O
.,O
and,O
found,O
lower,O
attack,CAUSE_OF_DEATH
rates,O
occurred,O
on,O
trains,O
or,O
flights,O
.,O
This,O
re,O
‐,O
sult,O
indicates,O
that,O
the,O
possibility,O
of,O
transmission,O
of,O
SARS,O
‐,O
COV2,O
on,O
flight,O
and,O
train,CRIMINAL_CHARGE
was,O
low,O
.,O
which,O
may,O
be,O
related,O
to,O
the,O
advanced,O
air,O
purification,O
system,O
and,O
sanitation,O
in,O
these,O
transportations,O
.,O
However,O
.,O
after,O
controlling,O
for,O
age,O
and,O
sex,O
.,O
the,O
results,O
of,O
logis,O
‐,O
tic,O
regression,O
did,O
not,O
find,O
significant,O
difference,O
across,O
various,O
transportations,O
except,O
in,O
the,O
Dream,O
Cruises,O
.,O
The,O
insignificance,O
may,O
be,O
attributed,O
to,O
the,O
limited,O
sample,O
size,O
and,O
the,O
risk,O
differ,O
‐,O
ence,O
may,O
actually,O
exist,O
.,O
Future,DATE
studies,O
with,O
larger,O
sample,O
should,O
be,O
conducted,O
to,O
explore,O
this,O
issue,O
and,O
provide,O
evidence,O
to,O
guide,O
the,O
development,O
of,O
prevention,O
in,O
transportations,O
.,O
Although,O
pre,O
‐,O
vious,O
studies,O
reported,O
that,O
both,O
asymptomatic,O
and,O
symptomatic,O
cases,O
could,O
infect,O
other,O
persons,O
[,O
26,NUMBER
‐,O
28,NUMBER
],O
.,O
the,O
differences,O
in,O
con,O
‐,O
tagiousness,O
at,O
different,O
phases,O
of,O
COVID,O
‐,O
19,NUMBER
remain,O
unclear,O
.,O
Our,O
study,O
shows,O
the,O
contagiousness,O
peaked,O
during,O
3,NUMBER
‐,O
4,DURATION
days,DURATION
after,O
symp,O
‐,O
tom,O
onset,O
.,O
which,O
is,O
consistent,O
with,O
previous,O
studies,O
.,O
which,O
showed,O
higher,O
virus,O
shedding,O
during,O
several,DURATION
days,DURATION
after,O
the,O
onset,O
of,O
symptoms,O
[,O
29,NUMBER
‐,O
31,NUMBER
],O
.,O
For,O
example,O
.,O
To,O
et,O
al.,O
found,O
that,O
salivary,O
viral,O
load,O
in,O
COVID,O
‐,O
19,NUMBER
cases,O
was,O
highest,O
during,O
the,DURATION
first,DURATION
week,DURATION
after,O
symptom,O
onset,O
.,O
and,O
the,O
viral,O
RNA,MISC
was,O
detected,O
25,DURATION
days,DURATION
after,O
symptom,O
onset,O
[,O
31,NUMBER
],O
.,O
In,O
addition,O
.,O
we,O
found,O
contacts,O
before,O
the,O
symptom,O
onset,O
could,O
also,O
lead,O
to,O
infection,CAUSE_OF_DEATH
.,O
which,O
indicates,O
the,O
transmission,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
incubation,O
period,O
.,O
Although,O
viral,O
shedding,O
before,O
symptom,O
onset,O
is,O
still,O
limited,O
.,O
Zou,PERSON
et,O
al,O
.,O
re,O
‐,O
ported,O
an,O
asymptomatic,O
patient,O
who,O
had,O
similar,O
amount,O
of,O
virus,O
to,O
those,O
symptomatic,O
cases,O
[,O
30,NUMBER
],O
.,O
Another,O
study,O
conducted,O
in,O
children,O
also,O
detected,O
positive,O
virus,O
before,O
onset,O
of,O
symptoms,O
in,O
several,O
children,O
cases,O
[,O
20,NUMBER
],O
.,O
These,O
findings,O
suggested,O
COVID,O
‐,O
19,NUMBER
could,O
be,O
transmitted,O
before,O
onset,O
of,O
symptoms,O
.,O
The,O
present,DATE
study,O
found,O
that,O
severe,O
index,O
cases,O
could,O
cause,O
higher,O
attack,CAUSE_OF_DEATH
rates,O
than,O
mild,O
cases,O
.,O
In,O
addition,O
.,O
compared,O
with,O
cases,O
with,O
fever,CAUSE_OF_DEATH
.,O
dizzy,O
.,O
myal,O
‐,O
gia,O
and,O
chill,O
caused,O
higher,O
infected,O
risks,O
to,O
their,O
contacts,O
.,O
while,O
cases,O
with,O
rhinorrhea,O
.,O
expectoration,O
and,O
chest,O
tightness,O
caused,O
lower,O
infected,O
risks,O
.,O
To,O
et,O
al.,O
s,O
study,O
showed,O
higher,O
virus,O
load,O
in,O
specimens,O
of,O
severe,O
patients,O
than,O
mild,O
patients,O
[,O
31,NUMBER
],O
.,O
which,O
verified,O
our,O
findings,O
.,O
However,O
.,O
studies,O
are,O
needed,O
to,O
de,O
‐,O
tect,O
the,O
virus,O
load,O
in,O
cases,O
with,O
different,O
clinical,O
symptoms,O
for,O
assessing,O
their,O
contagiousness,O
.,O
This,O
study,O
has,O
several,O
strengths,O
.,O
First,ORDINAL
.,O
our,O
study,O
includes,O
the,O
largest,O
number,O
of,O
close,O
contacts,O
of,O
COVID,O
‐,O
19,NUMBER
to,O
date,O
.,O
Second,ORDINAL
.,O
our,O
study,O
is,O
a,O
retrospec,O
‐,O
tive,O
cohort,O
study,O
.,O
which,O
provides,O
information,O
with,O
explicit,O
tem,O
‐,O
porality,O
for,O
causal,O
inference,O
and,O
the,O
recall,O
bias,O
was,O
reduced,O
.,O
Third,ORDINAL
.,O
we,O
estimated,O
the,O
attack,CAUSE_OF_DEATH
rates,O
and,O
infected,O
risks,O
for,O
dif,O
‐,O
ferent,O
contacts,O
.,O
which,O
is,O
helpful,O
for,O
identifying,O
susceptible,O
groups,O
to,O
develop,O
specific,O
protection,O
.,O
Fourth,ORDINAL
.,O
we,O
estimated,O
the,O
contagiousness,O
across,O
the,O
course,O
of,O
Some,O
limitations,O
also,O
need,O
to,O
be,O
noted,O
.,O
First,ORDINAL
.,O
although,O
we,O
used,O
a,O
large,O
dataset,O
with,O
more,O
than,O
ten,NUMBER
thousand,NUMBER
of,O
contacts,O
.,O
the,O
sample,O
size,O
of,O
cases,O
was,O
limited,O
in,O
some,O
subgroups,O
.,O
which,O
may,O
lead,O
to,O
insufficient,O
power,O
to,O
identify,O
the,O
statistical,O
significance,O
.,O
Second,ORDINAL
.,O
a,O
number,O
of,O
asymptomatic,O
infections,CAUSE_OF_DEATH
may,O
be,O
missed,O
and,O
their,O
close,O
contacts,O
can,O
not,O
be,O
iden,O
‐,O
tified,O
.,O
Third,ORDINAL
.,O
since,O
the,O
imperfect,O
sensitivity,O
of,O
the,O
RT,O
‐,O
PCR,O
test,O
.,O
some,O
potential,O
infections,CAUSE_OF_DEATH
among,O
close,O
contacts,O
may,O
be,O
missed,O
.,O
Fourth,ORDINAL
.,O
the,O
data,O
were,O
collected,O
by,O
a,O
variety,O
of,O
epidemi,O
‐,O
ological,O
investigation,O
groups,O
across,O
Guangdong,STATE_OR_PROVINCE
Province,LOCATION
.,O
Despite,O
using,O
the,O
same,O
protocol,O
.,O
the,O
implementation,O
may,O
have,O
inconsis,O
‐,O
tence,O
and,O
some,O
noise,O
may,O
be,O
introduced,O
.,O
Children,O
.,O
old,O
people,O
.,O
females,O
and,O
family,O
members,O
are,O
susceptible,O
to,O
be,O
infected,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
while,O
index,O
cases,O
in,O
incubation,O
period,O
had,O
lower,O
conta,O
‐,O
giousness,O
.,O
Our,O
findings,O
will,O
be,O
helpful,O
for,O
developing,O
targeted,O
prevention,O
and,O
control,O
strategies,O
to,O
combat,O
the,O
worldwide,O
pandem,O
‐,O
ic,O
.,O
Ethical,O
approval,O
and,O
consent,O
to,O
participate,O
Data,O
collection,O
and,O
analysis,O
of,O
cases,O
and,O
close,O
contacts,O
were,O
determined,O
by,O
the,O
National,ORGANIZATION
Health,ORGANIZATION
be,O
summarised,O
in,O
media,O
press,O
releases,O
from,O
the,O
Guangdong,ORGANIZATION
Provincial,ORGANIZATION
Center,ORGANIZATION
for,ORGANIZATION
Disease,ORGANIZATION
Control,ORGANIZATION
and,ORGANIZATION
Prevention,ORGANIZATION
.,O
Consent,O
for,O
publication,O
Not,O
applicable,O
.,O
Competing,O
interests,O
This,O
study,O
was,O
supported,O
by,O
[,O
the,O
National,O
Key,O
Research,O
and,O
Development,O
Program,O
of,O
China,COUNTRY
#,MONEY
1,MONEY
],O
under,O
Grant,O
[,O
number,O
2018YFA0606200,O
.,O
2018YFA0606202,O
],O
;,O
[,O
the,O
Science,ORGANIZATION
and,ORGANIZATION
Technology,ORGANIZATION
Program,ORGANIZATION
of,O
Guangdong,STATE_OR_PROVINCE
Province,O
#,MONEY
2,MONEY
],O
under,O
Grant,O
[,O
number,O
2018B020207006,O
.,O
2019B020208005,O
.,O
2019B111103001,O
],O
;,O
and,O
[,O
Guangzhou,CITY
Science,LOCATION
and,O
technology,O
Plan,O
Project,O
#,MONEY
3,MONEY
],O
under,O
Grant,PERSON
[,O
number,O
conceptualized,O
the,O
paper,O
.,O
TL,O
.,O
JFH,O
.,O
ZHC,O
and,O
GHH,O
analyzed,O
the,O
data,O
.,O
with,O
input,O
from,O
TS,O
.,O
SWC,O
.,O
PW,LOCATION
.,O
JLL,O
.,O
YHL,O
.,O
MJC,ORGANIZATION
.,O
JXH,O
.,O
JWN,O
.,O
LX,O
.,O
JPX,O
.,O
JXH,O
.,O
LFL,ORGANIZATION
.,O
QH,O
.,O
ZHR,O
.,O
APD,ORGANIZATION
.,O
WLZ,O
.,O
JSL,ORGANIZATION
.,O
XL,O
.,O
XHT,O
.,O
MK,O
.,O
LCG,O
.,O
ZHZ,O
.,O
DXG,O
.,O
GMC,ORGANIZATION
.,O
and,O
MRD,O
.,O
TL,O
.,O
WJL,O
.,O
HJZ,O
.,O
TS,O
.,O
JFH,O
.,O
ZHC,O
.,O
GHH,O
and,O
WJM,ORGANIZATION
wrote,O
the,O
Data,O
sharing,O
No,O
additional,O
data,O
avail,O
‐,O
able,O
.,O
We,O
thank,O
all,O
members,O
from,O
health,O
departments,O
and,O
CDCs,O
in,O
Guangdong,STATE_OR_PROVINCE
Province,LOCATION
for,O
their,O
contribution,O
in,O
data,O
collection,O
.,O
COVID,O
‐,O
19,NUMBER
control,O
and,O
prevention,O
.,O
Li,O
Q,O
.,O
Guan,PERSON
X,PERSON
.,O
Wu,PERSON
P,O
.,O
et,O
al,O
.,O
Ear,O
‐,O
ly,O
Transmission,MISC
Dynamics,MISC
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
of,O
Novel,O
Coronavirus,O
World,ORGANIZATION
Health,ORGANIZATION
Organization,ORGANIZATION
.,O
Coronavirus,O
disease,CAUSE_OF_DEATH
(,O
COVID,O
‐,O
19,NUMBER
),O
Situa,O
‐,O
tion,O
Report,O
152,NUMBER
.,O
2020,DATE
.,O
World,ORGANIZATION
Health,ORGANIZATION
Organization,ORGANIZATION
.,O
Coronavirus,O
disease,CAUSE_OF_DEATH
(,O
COVID,O
‐,O
19,NUMBER
),O
Situation,O
Report,O
52,NUMBER
.,O
2020,DATE
.,O
Glasser,PERSON
JW,PERSON
.,O
Hu,PERSON
‐,PERSON
pert,O
N,O
.,O
McCauley,PERSON
MM,O
.,O
et,O
al,O
.,O
Modeling,O
and,O
public,O
health,O
emergency,O
responses,O
:,O
Swanson,ORGANIZATION
KC,ORGANIZATION
.,O
Altare,O
C,O
.,O
Wesseh,PERSON
CS,O
.,O
et,O
al,O
.,O
Contact,O
trac,O
‐,O
ing,O
performance,O
during,O
the,O
Ebola,MISC
epidemic,O
Kang,O
M,O
.,O
Song,O
T,O
.,O
Zhong,PERSON
H,O
.,O
et,O
al,O
.,O
Contact,O
Tracing,O
for,O
Imported,O
Case,O
of,O
Middle,O
East,O
Respi,O
‐,O
ratory,O
Pang,O
X,O
.,O
Zhu,PERSON
Z,O
.,O
Xu,O
F,O
.,O
et,O
al,O
.,O
Evaluation,O
of,O
Control,O
Measures,O
Implemented,O
in,O
the,O
Severe,O
Acute,O
WHO,O
‐,O
China,COUNTRY
Joint,O
Mission,O
Members,O
.,O
Report,O
of,O
the,O
WHO,O
‐,O
China,COUNTRY
Joint,LOCATION
Mission,CITY
on,O
Coronavirus,O
Hellewell,O
J,O
.,O
Abbott,PERSON
S,O
.,O
Gimma,PERSON
A,O
.,O
et,O
al,O
.,O
Feasibility,O
of,O
controlling,O
COVID,O
‐,O
19,NUMBER
outbreaks,O
by,O
isolation,O
10,NUMBER
.,O
Keeling,ORGANIZATION
MJ,ORGANIZATION
.,O
Hollingsworth,PERSON
TD,O
.,O
Read,O
JM,O
.,O
The,O
Efficacy,O
of,O
Contact,O
Tracing,O
for,O
the,O
Containment,O
of,O
11,NUMBER
.,O
Du,O
RH,O
.,O
Liang,PERSON
LR,PERSON
.,O
Yang,PERSON
CQ,O
.,O
et,O
al,O
.,O
Predictors,O
of,O
mortality,O
for,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
pneumonia,CAUSE_OF_DEATH
12,NUMBER
.,O
Zhou,PERSON
F,PERSON
.,O
Yu,PERSON
T,PERSON
.,O
Du,PERSON
R,PERSON
.,O
et,O
al,O
.,O
Clinical,O
course,O
and,O
risk,O
factors,O
for,O
mortality,O
of,O
adult,O
inpatients,O
with,O
13,NUMBER
.,O
Bi,O
Q,O
.,O
Wu,PERSON
Y,PERSON
.,O
Mei,PERSON
S,PERSON
.,O
et,O
al,O
.,O
Epidemiology,O
and,O
transmission,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
391,NUMBER
cases,O
and,O
1286,DATE
of,O
14,NUMBER
.,O
Jing,PERSON
QL,PERSON
.,O
Liu,PERSON
MJ,PERSON
.,O
Zhang,PERSON
ZB,PERSON
.,O
et,O
al,O
.,O
Household,O
secondary,O
attack,CAUSE_OF_DEATH
rate,O
of,O
COVID,O
‐,O
19,NUMBER
and,O
associated,O
15,NUMBER
.,O
Cheng,PERSON
HY,PERSON
.,O
Jian,PERSON
SW,PERSON
.,O
Liu,PERSON
DP,O
.,O
et,O
al,O
.,O
Contact,O
Tracing,O
Assessment,O
of,O
COVID,O
‐,O
19,NUMBER
Transmission,ORGANIZATION
Dynamics,ORGANIZATION
in,O
Taiwan,COUNTRY
and,O
Risk,O
at,O
Different,O
Exposure,O
Periods,O
Before,O
and,O
After,O
Symptom,O
Onset,O
.,O
JAMA,ORGANIZATION
18,NUMBER
.,O
Lee,PERSON
P,O
.,O
Hu,O
Y,O
.,O
Chen,PERSON
P,PERSON
.,O
et,O
al,O
.,O
Are,O
children,O
less,O
susceptible,O
to,O
COVID,O
‐,O
19,NUMBER
?,O
J,O
Microbiol,O
Immunol,O
Infect,O
.,O
19,NUMBER
.,O
Wu,O
Z,O
.,O
McGoogan,PERSON
JM,PERSON
.,O
Characteristics,O
of,O
and,O
important,O
lessons,O
from,O
the,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
outbreak,O
in,O
China,COUNTRY
:,O
summary,O
of,O
a,O
report,O
of,O
72314,NUMBER
cases,O
from,O
the,O
Chinese,ORGANIZATION
Center,ORGANIZATION
for,ORGANIZATION
Disease,ORGANIZATION
20,NUMBER
.,O
Xu,O
Y,O
.,O
Li,PERSON
X,PERSON
.,O
Zhu,PERSON
B,PERSON
.,O
et,O
al,O
.,O
Characteristics,O
of,O
pediatric,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
and,O
potential,O
evidence,O
21,NUMBER
.,O
Mehta,ORGANIZATION
NS,ORGANIZATION
.,O
Mytton,ORGANIZATION
OT,ORGANIZATION
.,O
Mullins,ORGANIZATION
EWS,ORGANIZATION
.,O
et,O
al,O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
(,O
COVID,O
‐,O
19,NUMBER
),O
:,O
What,O
do,O
we,O
know,O
22,NUMBER
.,O
Dong,PERSON
Y,PERSON
.,O
Mo,PERSON
X,PERSON
.,O
HuY,O
.,O
et,O
al,O
.,O
Epi,O
‐,O
demiological,O
Characteristics,O
of,O
2143,DATE
Pediatric,O
Patients,O
With,O
2019,DATE
23,NUMBER
.,O
Wenham,LOCATION
C,O
.,O
Smith,PERSON
J,PERSON
.,O
Morgan,O
R.,O
COVID,O
‐,O
19,NUMBER
:,O
the,O
gendered,O
impacts,O
of,O
the,O
outbreak,O
.,O
Lance,PERSON
Boniol,PERSON
M,O
.,O
McIsaac,PERSON
M,O
.,O
Xu,PERSON
L,PERSON
.,O
et,O
al,O
.,O
Gender,O
equity,O
in,O
the,O
health,O
workforce,O
:,O
Analysis,O
of,O
104,NUMBER
countries,O
Geneva,CITY
:,O
World,O
25,NUMBER
.,O
Pang,O
X,O
.,O
Yang,PERSON
P,O
.,O
Li,PERSON
S,PERSON
.,O
et,O
al,O
.,O
Pandemic,O
(,O
H1N1,O
),O
2009,DATE
among,O
quarantined,O
close,O
contacts,O
.,O
Beijing,CITY
.,O
26,NUMBER
.,O
Rothe,PERSON
C,O
.,O
Schunk,PERSON
M,O
.,O
Soth,PERSON
‐,PERSON
mann,O
P,O
.,O
et,O
al,O
.,O
Transmission,O
of,O
2019,DATE
‐,O
nCoV,O
infection,CAUSE_OF_DEATH
from,O
an,O
27,NUMBER
.,O
Bai,O
Y,O
.,O
Yao,PERSON
L,PERSON
.,O
Wei,PERSON
T,PERSON
.,O
et,O
al,O
.,O
Presumed,O
Asymptomatic,O
Carrier,O
Trans,O
‐,O
mission,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
JAMA,ORGANIZATION
.,O
28,NUMBER
.,O
Chan,RELIGION
JF,O
‐,O
W,O
.,O
Yuan,PERSON
S,PERSON
.,O
Kok,PERSON
K,O
‐,O
H,O
.,O
et,O
al,O
.,O
A,O
familial,O
cluster,O
of,O
pneumonia,CAUSE_OF_DEATH
associated,O
with,O
the,O
2019,DATE
novel,O
coronavirus,O
indicating,O
person,O
‐,O
to,O
‐,O
person,O
transmission,O
:,O
a,O
study,O
of,O
a,O
family,O
cluster,O
.,O
Lancet,ORGANIZATION
.,O
2020,DATE
;,O
29,NUMBER
.,O
Woelfel,PERSON
R,PERSON
.,O
Corman,PERSON
VM,PERSON
.,O
Gugge,O
‐,O
mos,DURATION
W,O
.,O
et,O
al,O
.,O
Clinical,O
presentation,O
and,O
virological,O
assessment,O
of,O
hospitalized,O
cases,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
in,O
a,O
travel,O
‐,O
asso,O
‐,O
ciated,O
transmission,O
cluster,O
.,O
medRxiv,O
.,O
2020,DATE
.,O
30,NUMBER
.,O
Zou,PERSON
L,PERSON
.,O
Ruan,PERSON
F,PERSON
.,O
Huang,PERSON
M,O
.,O
et,O
al,O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
Viral,O
Load,O
in,O
Upper,O
Respiratory,O
Speci,O
‐,O
mens,O
of,O
31,NUMBER
.,O
To,O
KK,O
‐,O
W,O
.,O
Tsang,PERSON
OT,O
‐,O
Y,O
.,O
Leung,PERSON
W,O
‐,O
S,O
.,O
et,O
al,O
.,O
Temporal,O
pro,O
‐,O
files,O
of,O
viral,O
load,O
in,O
posterior,O
oropharyngeal,O
saliva,O
samples,O
and,O
serum,O
antibody,O
responses,O
during,O
infection,CAUSE_OF_DEATH
by,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
:,O
an,O
ob,O
‐,O
servational,O
cohort,O
Places,O
of,O
quarantine,O
At,O
home,O
Centralized,O
sta,O
‐,O
tions,O
Contact,O
circumstances,O
Social,O
activities,O
Public,O
transporta,O
‐,O
tion,O
*,O
Private,TITLE
car,O
The,O
Dream,O
Cruises,O
Relationship,O
with,O
index,O
cases,O
Family,O
members,O
Family,O
members,O
(,O
non,O
‐,O
spouse,O
),O
Close,O
relatives,O
Other,O
relatives,O
Social,O
activity,O
contacts,O
Transportation,O
contacts,O
Health,O
care,O
workers,O
Infection,CAUSE_OF_DEATH
spectrum,O
of,O
contacts,O
No,O
infection,CAUSE_OF_DEATH
Asympto,O
‐,O
matic,O
infections,CAUSE_OF_DEATH
Mild,O
confirmed,O
cases,O
Moderate,O
confirmed,O
cases,O
Severe,O
confirmed,O
cases,O
Critically,O
severe,O
confirmed,O
cases,O
Dead,O
cases,O
*,O
:,O
Indicate,O
other,O
public,O
transportations,O
mainly,O
including,O
bus,O
.,O
taxi,O
.,O
subway,O
.,O
ferry,O
.,O
etc,O
.,O
Total,O
contacts,O
Total,O
infections,CAUSE_OF_DEATH
Attack,CAUSE_OF_DEATH
Rate,O
(,O
%,O
),O
Family,O
members,O
(,O
non,O
‐,O
spouse,O
),O
Close,O
relatives,O
Other,O
relatives,O
Social,O
activity,O
contacts,O
Transportation,O
contacts,O
Health,O
care,O
workers,O
Public,O
transportation,O
*,O
Private,TITLE
car,O
The,O
Dream,O
Cruises,O
Age,O
of,O
contacts,O
(,O
years,DURATION
),O
Relationship,O
to,O
the,O
index,O
case,O
Contacts,O
on,O
different,O
transportations,O
*,O
:,O
Indicate,O
other,O
public,O
transporta,O
‐,O
tions,O
mainly,O
including,O
bus,O
.,O
taxi,O
.,O
subway,O
.,O
ferry,O
.,O
etc,O
.,O
Total,O
con,O
‐,O
tacts,O
Total,O
infections,CAUSE_OF_DEATH
Attack,CAUSE_OF_DEATH
Rate,O
(,O
%,O
),O
Incubation,O
period,O
Sympto,O
‐,O
matic,O
period,O
Disease,CAUSE_OF_DEATH
history,O
of,O
confirmed,O
index,O
cases,O
#,O
Contacts,O
to,O
the,O
index,O
cases,O
at,O
different,O
time,O
(,O
days,DURATION
to,O
the,O
symptom,O
onset,O
),O
*,O
Critically,O
severe,O
Clinical,O
severity,O
of,O
index,O
case,O
*,O
:,O
Minus,O
number,O
indicates,O
days,DURATION
before,O
the,O
symptom,O
onset,O
.,O
plus,O
number,O
indicates,O
the,DURATION
days,DURATION
after,O
the,O
symptom,O
onset,O
in,O
confirmed,O
cases,O
.,O
and,O
zero,NUMBER
in,O
‐,O
dicates,O
the,DATE
day,DATE
of,O
symptom,O
onset,O
.,O
In,O
order,O
to,O
precisely,O
estimate,O
the,O
contacting,O
time,O
.,O
only,O
the,O
pairs,O
with,O
only,O
one,NUMBER
index,O
case,O
and,O
one,NUMBER
secondary,O
case,O
were,O
included,O
.,O
identified,O
from,O
the,O
quaran,O
‐,O
tined,O
contacts,O
in,O
Guangdong,STATE_OR_PROVINCE
Province,LOCATION
.,O
Panel,O
A,O
:,O
In,O
contacts,O
with,O
different,O
ages,O
;,O
Panel,O
B,O
:,O
In,O
males,O
and,O
females,O
;,O
Panel,O
C,O
:,O
In,O
con,O
‐,O
tacts,O
who,O
had,O
different,O
relationships,O
to,O
the,O
index,O
case,O
;,O
Panel,O
D,O
:,O
In,O
contacts,O
exposed,O
to,O
the,O
index,O
cases,O
on,O
different,O
transporta,O
‐,O
tions,O
;,O
Panel,O
E,O
:,O
In,O
contacts,O
exposed,O
to,O
the,O
index,O
cases,O
at,O
differ,O
‐,O
ent,O
time,O
;,O
Panel,O
F,O
:,O
In,O
contacts,O
exposed,O
to,O
the,O
index,O
cases,O
in,O
dif,O
‐,O
ferent,O
course,O
of,O
disease,CAUSE_OF_DEATH
;,O
Panel,O
G,O
:,O
In,O
contacts,O
exposed,O
to,O
the,O
in,O
‐,O
dex,O
cases,O
with,O
different,O
clinical,O
severity,O
;,O
Panel,O
H,O
:,O
In,O
contacts,O
exposed,O
to,O
the,O
index,O
cases,O
with,O
different,O
clinical,O
symptoms,O
.,O
Confirmed,O
cases,O
Asymptomatic,MISC
infections,CAUSE_OF_DEATH
Daily,SET
number,O
of,O
quaran,O
‐,O
tined,O
contacts,O
Daily,SET
number,O
of,O
infections,CAUSE_OF_DEATH
Daily,SET
number,O
of,O
quaran,O
‐,O
tined,O
contacts,O
Adjusted,O
for,O
age,O
and,O
/,O
or,O
sex,O
Risk,O
factors,O
associat,O
‐,O
ed,O
with,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
:,O
a,O
retrospective,O
cohort,O
study,O
based,O
on,O
contacts,O
tracing,O
Tao,O
Liu1,O
*,O
.,O
Wenjia,O
Liang2,O
*,O
.,O
Haojie,O
Zhong2,O
*,O
.,O
Jian,PERSON
‐,PERSON
feng,O
He2,O
*,O
.,O
Zihui,O
Chen1,O
*,O
.,O
Guanhao,O
He1,O
*,O
.,O
Tie,O
Song2,O
.,O
Shaowei,O
Chen1,O
.,O
Ping,O
Wang1,O
.,O
Jialing,O
Li2,O
.,O
Yunhua,O
Lan2,O
.,O
Mingji,O
Cheng2,O
.,O
Jinxu,PERSON
Huang2,O
.,O
Jiwei,PERSON
Niu2,PERSON
.,O
Liang,PERSON
Xia2,PERSON
.,O
Jianpeng,PERSON
Xiao1,PERSON
.,O
Jianxiong,PERSON
Hu1,PERSON
.,O
Lifeng,PERSON
Lin2,PERSON
.,O
Qiong,PERSON
Huang2,PERSON
.,O
Zuhua,PERSON
Rong1,PERSON
.,O
Aiping,O
Deng2,O
.,O
Weilin,PERSON
Zeng1,O
.,O
Jiansen,PERSON
Li2,PERSON
.,O
Xing,PERSON
Li1,PERSON
.,O
Xiaohua,PERSON
Tan2,PERSON
.,O
Min,DURATION
Kang2,O
.,O
Lingchuan,PERSON
Guo1,O
.,O
Zhihua,PERSON
Zhu1,PERSON
.,O
Dexin,PERSON
Gong1,PERSON
.,O
Guimin,O
Chen1,O
.,O
Moran,PERSON
Dong1,O
.,O
Wenjun,PERSON
Ma1,O
Control,ORGANIZATION
and,ORGANIZATION
Prevention,ORGANIZATION
.,O
Guangzhou,CITY
.,O
China,COUNTRY
.,O
2,NUMBER
.,O
Guangdong,STATE_OR_PROVINCE
Pro,O
‐,O
vincial,O
Center,ORGANIZATION
for,ORGANIZATION
Disease,ORGANIZATION
Control,ORGANIZATION
and,ORGANIZATION
Prevention,ORGANIZATION
.,O
Guangzhou,CITY
.,O
China,COUNTRY
.,O
Correspondence,O
to,O
:,O
Disease,CAUSE_OF_DEATH
Control,O
and,O
Prevention,O
.,O
Guangzhou,CITY
511430,NUMBER
.,O
China,COUNTRY
1.1,NUMBER
Definitions,O
of,O
suspect,O
and,O
confirmed,O
cases,O
Considering,O
both,O
the,O
following,O
epidemiological,O
history,O
and,O
clinical,O
manifestations,O
:,O
Epidemiological,O
history,O
(,O
1,NUMBER
),O
History,O
of,O
travel,O
to,O
or,O
residence,O
in,O
Wuhan,CITY
and,O
its,O
surrounding,O
areas,O
.,O
or,O
in,O
other,O
communities,O
where,O
cases,O
have,O
been,O
reported,O
within,O
14,DURATION
days,DURATION
prior,O
to,O
the,O
onset,O
of,O
the,O
disease,CAUSE_OF_DEATH
;,O
(,O
2,NUMBER
),O
In,O
contact,O
with,O
novel,O
coronavirus,O
infected,O
people,O
(,O
with,O
positive,O
results,O
for,O
the,O
nucle,O
‐,O
ic,O
acid,O
test,O
),O
within,O
14,DURATION
days,DURATION
prior,O
to,O
the,O
onset,O
of,O
the,O
disease,CAUSE_OF_DEATH
;,O
(,O
3,NUMBER
),O
In,O
contact,O
with,O
patients,O
who,O
have,O
fever,CAUSE_OF_DEATH
or,O
respiratory,O
symp,O
‐,O
toms,O
from,O
Wuhan,CITY
and,O
its,O
surrounding,O
area,O
.,O
or,O
from,O
communities,O
where,O
confirmed,O
cases,O
have,O
been,O
reported,O
within,O
14,DURATION
days,DURATION
before,O
the,O
onset,O
of,O
the,O
disease,CAUSE_OF_DEATH
;,O
or,O
(,O
4,NUMBER
),O
Clustered,O
cases,O
(,O
2,NUMBER
or,O
more,O
cases,O
with,O
fever,CAUSE_OF_DEATH
and,O
/,O
or,O
respiratory,O
symptoms,O
in,O
a,O
small,O
area,O
such,O
Clin,O
‐,O
ical,O
manifestations,O
(,O
1,NUMBER
),O
Fever,CAUSE_OF_DEATH
and,O
/,O
or,O
respiratory,O
symptoms,O
;,O
(,O
2,NUMBER
),O
The,O
aforementioned,O
imaging,O
characteristics,O
of,O
novel,O
coronavirus,O
pneumonia,CAUSE_OF_DEATH
(,O
SARS,O
‐,O
COV,O
‐,O
2,NUMBER
),O
;,O
(,O
3,NUMBER
),O
Normal,O
or,O
decreased,O
WBC,ORGANIZATION
count,TITLE
.,O
normal,O
or,O
decreased,O
lymphocyte,O
count,TITLE
in,O
the,O
early,O
stage,O
of,O
A,O
suspect,O
case,O
has,O
any,O
of,O
the,O
epidemiological,O
history,O
plus,O
any,O
two,NUMBER
clinical,O
manifestations,O
or,O
all,O
three,NUMBER
clinical,O
manifestations,O
if,O
there,O
is,O
no,O
clear,O
epidemiological,O
history,O
.,O
Confirmed,O
cases,O
Suspect,O
cases,O
with,O
one,NUMBER
of,O
the,O
following,O
etiological,O
or,O
serological,O
evidences,O
:,O
(,O
1,NUMBER
),O
Real,O
‐,O
time,O
fluorescent,O
RT,O
‐,O
PCR,O
indicates,O
positive,O
for,O
new,O
coro,O
‐,O
navirus,O
nucleic,O
acid,O
;,O
(,O
2,NUMBER
),O
Viral,O
gene,O
sequence,O
is,O
highly,O
homolo,O
‐,O
gous,O
to,O
known,O
new,O
coronaviruses,O
.,O
with,O
the,O
acute,O
phase,O
.,O
1.2,NUMBER
Def,O
‐,O
inition,O
of,O
close,O
contacts,O
to,O
the,O
index,O
case,O
A,O
contact,O
is,O
a,O
person,O
who,O
experienced,O
any,O
one,NUMBER
of,O
the,O
following,O
exposures,O
during,O
the,O
2,NUMBER
days,DURATION
before,O
and,O
the,DURATION
14,DURATION
days,DURATION
after,O
the,O
onset,O
of,O
symptoms,O
of,O
a,O
probable,O
or,O
confirmed,O
case,O
:,O
(,O
1,NUMBER
),O
Face,O
‐,O
to,O
‐,O
face,O
contact,O
with,O
a,O
prob,O
‐,O
able,O
or,O
confirmed,O
case,O
within,O
1,NUMBER
meter,O
and,O
for,O
more,O
than,O
15,NUMBER
(,O
2,NUMBER
),O
Direct,O
physical,O
contact,O
with,O
a,O
probable,O
or,O
confirmed,O
case,O
.,O
(,O
3,NUMBER
),O
Direct,O
care,O
for,O
a,O
patient,O
with,O
probable,O
or,O
confirmed,O
COVID,O
‐,O
19,NUMBER
disease,CAUSE_OF_DEATH
without,O
using,O
proper,O
personal,O
protective,O
equipment,O
.,O
or,O
(,O
4,NUMBER
),O
Other,O
situations,O
as,O
indicated,O
by,O
local,O
risk,O
assessments,O
.,O
Note,O
:,O
for,O
confirmed,O
asymptomatic,O
cases,O
.,O
the,O
period,O
of,O
contact,O
is,O
measured,O
as,O
the,DURATION
2,DATE
days,DATE
before,DATE
through,DATE
the,DATE
14,DATE
days,DATE
after,O
the,O
date,O
on,O
which,O
the,O
sample,O
was,O
taken,O
which,O
led,O
to,O
confirmation,O
.,O
1.3,NUMBER
Definition,O
of,O
asymptomatic,O
infection,CAUSE_OF_DEATH
Asymptomatic,MISC
infection,CAUSE_OF_DEATH
was,O
defined,O
as,O
those,O
whose,O
specimens,O
are,O
detected,O
with,O
positive,O
of,O
SARSCOV,O
‐,O
2,NUMBER
virus,O
.,O
but,O
have,O
no,O
clinical,O
symptoms,O
including,O
fever,CAUSE_OF_DEATH
.,O
cough,O
.,O
etc,O
.,O
Average,O
number,O
of,O
contacts,O
linked,O
to,O
one,NUMBER
index,O
case,O
*,O
Contacts,O
divided,O
by,O
contact,O
circumstances,O
Social,O
activity,O
Con,O
‐,O
tacts,O
divided,O
by,O
relationship,O
to,O
index,O
cases,O
Household,O
member,O
So,O
‐,O
cial,O
activity,O
contact,O
Transportation,ORGANIZATION
contact,O
Health,O
care,O
worker,O
Average,O
days,DURATION
from,O
exposure,O
to,O
quarantine,O
Average,O
days,DURATION
of,O
quaran,O
‐,O
tine,O
*,O
:,O
The,O
parameter,O
was,O
estimated,O
in,O
the,O
total,O
contacts,O
.,O
clin,O
‐,O
ical,O
symptoms,O
Clinical,O
symptoms,O
of,O
index,O
cases,O
Number,O
of,O
contacts,O
Total,O
infections,CAUSE_OF_DEATH
Attack,CAUSE_OF_DEATH
Rate,O
(,PERCENT
%,PERCENT
),O
Shortness,O
of,O
breath,O
Nasal,MISC
con,O
‐,O
gestion,O
Chest,O
tightness,O
Poor,O
appetite,O
Abdominal,O
pain,O
Chest,O
pain,O
Adjusted,O
for,O
age,O
and,O
sex,O
.,O
Age,O
(,O
years,DURATION
),O
of,O
the,O
index,O
case,O
(,O
number,O
of,O
infections,CAUSE_OF_DEATH
/,O
number,O
of,O
contacts,O
.,O
%,O
),O
Age,O
of,O
contact,O
Age,O
of,O
the,O
index,O
case,O
(,O
years,DURATION
),O
Age,O
of,O
contact,O
Adjusted,O
for,O
sex,O
.,O
